Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
BIOCRYST PHARMACEUTICALS INC (BCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/23/2022 8-K Quarterly results
Docs: "BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones"
11/03/2021 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones"
08/06/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
Docs: "BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones"
03/05/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2019 Financial Results"
05/08/2019 8-K Quarterly results
Docs: "BioCryst Reports First Quarter 2019 Financial Results"
03/04/2019 8-K Quarterly results
Docs: "BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results",
"BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development"
11/06/2018 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2018 Financial Results APeX-2 study enrollment completed, results on-track for Q2 2019"
08/07/2018 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2018 Financial Results"
05/08/2018 8-K Quarterly results
Docs: "BioCryst Reports First Quarter 2018 Financial Results"
11/07/2017 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2017 Financial Results"
08/07/2017 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2017 Financial Results"
05/04/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2016 Financial Results"
08/04/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
02/23/2016 8-K Quarterly results
Docs: "BioCryst Reports Fourth Quarter & Full Year 2015 Financial Results"
11/05/2015 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2015 Financial Results"
08/07/2015 8-K Quarterly results
05/08/2015 8-K Quarterly results
Docs: "BioCryst Reports First Quarter 2015 Financial Results"
02/18/2015 8-K Quarterly results
Docs: "BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results"
11/06/2014 8-K Quarterly results
Docs: "BioCryst Reports Third Quarter 2014 Financial Results"
08/05/2014 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2014 Financial Results"
05/08/2014 8-K Quarterly results
Docs: "BIOCRYST REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS"
02/26/2014 8-K Quarterly results
Docs: "Amendment #17 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services",
"BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS",
"BIOCRYST ANNOUNCES PERAMIVIR NDA ACCEPTANCE BY THE FDA Research Triangle Park, North Carolina - February 25, 2014 - BioCryst Pharmaceuticals, Inc. , a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for intravenous peramivir that was submitted to the FDA in December 2013. The FDA assigned the NDA a standard review time, resulting in a PDUFA action date of December 23, 2014. The FDA has informed BioCryst that at this time, it does not plan to hold an Advisory Committee review of the NDA. “We are pleased that BioCryst's first NDA filing has been accepted by the FDA. We believe the approval of peramivir and its mode..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy